

1 **Solid state characterization of a 5'-O-oxalatoyl prodrug of zidovudine (azidothymidine)**

2

3 Diego E. Kassuha,^{1,2} Flavia P. Bruno,^{1,3} Gustavo A Monti,⁴ Norma R. Sperandeo^{1*}

4

5 ¹Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Departamento de Ciencias
6 Farmacéuticas and UNITEFA-CONICET. Haya de la Torre y Medina Allende, Ciudad
7 Universitaria, X5000HUA, Córdoba, Argentina.

8 ²Present address: Instituto de Investigaciones en Ciencias Químicas. Facultad de Ciencias
9 Químicas y Tecnológicas. Universidad Católica de Cuyo, San Juan, Argentina.

10 ³Present address: Laboratorio Fresenius Kabi, Del Comercio 757, X5016JSA Córdoba,
11 Argentina.

12 ⁴ Universidad Nacional de Córdoba. Facultad de Astronomía, Matemática, Física y
13 Computación. -IFEG-CONICET, Ciudad Universitaria, X5000HUA Córdoba, Argentina.

14

15

16

17 ***Corresponding author:** Prof. Dr. Norma R. Sperandeo, e-mail: nrscor@fcq.unc.edu.ar

18

TE: +54 351 5353865.

19

20

21

22

23

24

25 **Abstract**

26 The importance of polymorphism in pharmaceuticals makes its study relevant. The aim of this
27 study was to investigate the solid-state forms in which 3'-azido-2',3'-dideoxy-5'-O-oxalatoyl-
28 thymidinic acid (AZT-Ac), a zidovudine (AZT) prodrug with improved pharmacokinetic
29 properties, may exist. Samples were prepared using different crystallization conditions, and
30 characterized using powder X-ray diffraction, solid state nuclear magnetic resonance,
31 differential scanning calorimetry, thermogravimetry and hot stage microscopy.
32 Pharmaceutical relevant properties such as solid-state stability and intrinsic dissolution rate
33 (IDR) at 37 °C in simulated gastric fluid (SGF) were also evaluated. AZT-Ac was found able
34 to exist as a crystalline polymorph (AZT-Ac-C) and an amorphous phase (AZT-Ac-A), which
35 were thoroughly characterized. At 40 °C/75% RH, AZT-Ac-A in part devitrified to AZT-Ac-
36 C, and partially hydrolyzed to AZT after 7 and 14 days of storage, respectively. AZT-Ac-C
37 was physically stable at 40 °C/75% RH but partly hydrolyzed to AZT after 14 days of
38 storage. In SGF, AZT-Ac-C exhibited a linear ID profile and provided an ID rate of 0.494
39 mg/min/cm² while AZT-Ac-A exhibited a nonlinear profile. Therefore, the crystalline form
40 demonstrated advantages over the amorphous one in terms of solid state stability and IDR, but
41 approaches to enhance its stability should be considered for further formulation of this
42 prodrug.

43

44

45 **Keywords:** crystallization, differential scanning calorimetry, drugs, Nuclear Magnetic

46 Resonance, nucleoside inhibitors, X-ray diffraction.

47 1. Introduction

48 Zidovudine (azidothymidine) (AZT, Figure 1a) was the first active pharmaceutical
49 ingredient to be approved by the Food and Drug Administration for the treatment of Acquired
50 Immunodeficiency Syndrome (AIDS) in humans, and is still in use as part of the highly active
51 antiretroviral therapy (HAART) regimen (Shey et al., 2013). Although its efficacy has long
52 been demonstrated, AZT has various unfavorable aspects that constitute major concerns, such
53 as cellular toxicity (D'Andrea et al., 2008) and suboptimal pharmacokinetic properties
54 (Barbier et al., 2000; Narciso et al., 2014; Eilers et al., 2008). Among the clinical
55 circumstances of AZT toxicity there are numerous hematological effects, suppression of bone
56 marrow cell functions, liver disorders, myopathies, etc. (Khandazhinskaya and Shirokova,
57 2013). In addition, AZT exhibits short plasma half-life ($t_{1/2} \approx 1$ h) (Barbier et al., 2000), low
58 plasma protein-binding capacity (Narciso et al., 2014) and incapacity to reach effective
59 concentrations in viral reservoir tissues (Eilers et al., 2008). For this reason, AZT has to be
60 administered frequently and at high doses, thereby increasing the incidence of unwanted side
61 effects that often compromised the adherence of the patient to the anti-HIV treatment (Narciso
62 et al., 2014; Quevedo and Briñón, 2009).

63 Several strategies have been applied in order to enhance the oral bioavailability of AZT
64 as well as to prolong its elimination half-life (De Clercq, 2007), with the preparation of
65 prodrugs being a widely applied methodology (D'Andrea et al., 2008; Khandazhinskaya and
66 Shirokova, 2013; Quevedo and Briñón, 2009; Dalpiaz et al., 2012; Moroni et al., 2002;
67 Parang et al., 2000; Quevedo et al., 2008; Raviolo et al., 2009; Solyev et al., 2012; Ribone
68 et al., 2016). Among these prodrugs, 3'-azido-2',3'-deoxy-5'-O-oxalatoyl-thymidine (AZT-
69 Ac, Figure 1b) exhibited anti-HIV potency, low cytotoxicity and improved *in vitro*
70 permeability. In fact, it permeates the rat intestinal segment at a lower rate than AZT, but
71 resists enzymatic hydrolysis with no evidence of saturable transport mechanisms in the

72 jejunum or the proximal ileum (as the case of AZT) and, has an extended plasma half-life in
73 rats (Quevedo and Briñón, 2009). AZT-Ac also displayed high stability under acidic
74 conditions (pH 2) for 48 h, and suffered hydrolysis at pH 7.2 but its calculated $t_{1/2}$ was 12.8 h
75 (Ribone et al., 2016).

76 Considering that AZT-Ac is a prodrug of AZT with improved hydrolytic and
77 pharmacokinetic properties, and that thymidine nucleosides such as AZT and stavudine
78 exhibit crystalline polymorphism (Gandhi et al., 2000; Soares et al., 2013), the goal of this
79 study was to investigate the existence of different polymorphs of AZT-Ac in order to support
80 the development effort. To this aim, we subjected AZT-Ac to a polymorph screen using
81 several solid form screening techniques. We isolated only two solid forms, which were
82 characterized by means of powder X-ray diffraction (PXRD), solid state nuclear magnetic
83 resonance (SS ^{13}C NMR), differential scanning calorimetry (DSC), thermogravimetry (TG)
84 and hot-stage microscopy (HSM). The effects of temperature and moisture on the chemical
85 and physical stabilities of both solid forms of AZT-Ac were investigated at 40 °C/75%
86 relative humidity (RH) along with their disc intrinsic dissolution behavior in simulated gastric
87 fluid without pepsin at 37 °C in order to compare their solid state stabilities and dissolution
88 behaviors.

89

90 **2. Material and methods**

91 2.1 Materials

92 AZT was generously provided by Filaxis Laboratories (Buenos Aires, Argentina).
93 AZT-Ac raw material (AZT-Ac-r) was synthesized and purified following a described
94 procedure (Moroni et al., 2002). Precoated silica gel 60 F254 plates (Merck KGaA,
95 Germany), filter paper (2.7 μm , Whatman 542, UK) and nylon membranes (0.45 μm , Pall
96 Corporation, USA) were commercially acquired. All the solvents used were of analytical

97 grade, and Milli-Q[®] water (Millipore, Bedford, USA) was also utilized. For thin layer
98 chromatography (TLC) analyses, ethyl acetate-acetone-methanol 5:3:2 v/v, and pre-coated
99 plates of silica gel 60 F254 (Merck Chemicals) were used as the eluting solvent system and
100 stationary phase, respectively. Spots were visualized with UV light and iodide vapors.

101

102 2.2 Preparation of AZT-Ac forms

103 In search of different polymorphs for AZT-Ac a variety of solid form screening
104 techniques were used, which included crystallization (slow and fast) from solution,
105 antisolvent precipitation, vapor diffusion crystallization (Cunha, 2008), polymer induced
106 heteronucleation (Price et al., 2005) and lyophilization (Kassuha et al., 2015). Samples
107 generated by these techniques were initially analyzed by means of TLC for chemical purity,
108 finding that they were chromatographically pure, as no other spots than that of AZT-Ac were
109 detected. Eventually, only two different solid forms were obtained, which will be reported in
110 this paper. These two forms were named hereafter as AZT-Ac-C and AZT-Ac-A, and were
111 reproducibly obtained using the following procedures:

112 *AZT-Ac-C*: a saturated solution of AZT-Ac-r was prepared in acetonitrile at 20-25 °C
113 (RT), filtered (Whatman 532 paper) into a beaker. The beaker was covered with filter paper
114 and allowed to evaporate at room temperature (RT, 20-25 °C) in the dark. Then, the isolated
115 crystals were stored in a desiccator under CaCl₂.

116 *AZT-Ac-A*: a *t*-butanol-water (20:80, v/v) solution of AZT-Ac-r (30 mg/mL) was frozen
117 in air liquid and lyophilized at -40 °C for 24 h (Freezone 6, Labconco[®], USA). The resultant
118 solid was subjected to a secondary drying in a desiccator (vacuum, RT, P₂O₄) for 24 h and
119 stored at -20 °C in a tightly closed vial till analyzed.

120

121

122 2.3 PXRD

123 PXRD patterns were collected at RT on a X'PERT PRO X-ray diffractometer
124 (PANalytical, The Netherlands) fitted with a Copper tube (Cu $K\alpha = 1.54178 \text{ \AA}$) and a Ni
125 filter, with the X-ray generator being set at a voltage of 40 kV and a current of 30 mA.
126 Samples were analyzed with a step size of $0.05^\circ 2\theta$ and a step time of 3 s from 3 to $35^\circ 2\theta$,
127 using a 25 mm diameter Si single crystal holder.

128

129 2.4 SS ^{13}C NMR

130 SS ^{13}C NMR spectra were recorded at room temperature [Bruker Avance II spectrometer
131 operating at 300.13 MHz (protons) and 75.47 MHz (carbons), equipped with a 4 mm MAS
132 probe] using the CP/MAS sequence with proton decoupling during acquisition. Adamantane
133 was used as an external reference for the ^{13}C spectra and to set the Hartmann–Hahn matching
134 condition in the cross-polarization experiments. The spinning rate, recycling time, contact
135 time during CP and the acquisition time were 9 kHz, 30 s, 2 ms and 41 ms, respectively. The
136 numbers of transients were 256 and the SPINAL 64 sequence was used for decoupling during
137 acquisition with the proton decoupling field H_{1H} satisfying $\omega_{1H}/(2\pi) = \gamma H_{1H}/(2\pi) = 78 \text{ kHz}$.
138 The quaternary carbon edition spectra was acquired with the non-quaternary suppression
139 (NQS) sequence, with the ^1H and ^{13}C radio frequency fields being removed during $40 \mu\text{s}$ after
140 CP and before the acquisition. This delay allowed the carbon magnetization to decay because
141 of ^1H – ^{13}C dipolar coupling, resulting in spectra where CH and CH_2 were substantially
142 removed. Assignment of the ^{13}C resonances was accomplished with the aid of NQS
143 experiments and residual dipolar coupling in the solid-state and by comparison with the ^{13}C
144 spectrum ($\text{DMSO-}d_6$) of AZT-Ac-r.

145

146

147 2.5 DSC, TG and HSM

148 DSC and TG measurements were recorded on MDSC 2920 and TG 2950 analyzers (TA
149 Instruments Inc., USA), respectively. Samples (1-2 mg) were heated in non-hermetically
150 sealed aluminum pans, using a heating rate of 10 °C/min and a nitrogen (99.99 %) purge of 50
151 mL/min. The DSC and TG temperature axes were calibrated with indium (99.99 %, *m.p.*156.60 °C) and the Curie point of Ni (358.14 °C), respectively. Empty aluminum pans
152 were used as references. Data were analyzed using the Universal Analysis 2000 software (TA
153 Instruments Inc.). The physical and morphological changes that occurred in the samples
154 during heating were observed through a microscope fitted with a Kofler hot stage (Leitz,
155 Wetzlar, Germany) at a constant rate of 8 °C/min.

157

158 2.6 Solid-state stability

159 To investigate the effect of storage temperature and moisture on the physical and
160 chemical stabilities of the samples, 200 mg of each solid form (*n*= 2) were stored at 40
161 °C/75% RH (open glass vials inside a drying pistol (ISV, Argentina) filled with a saturated
162 aqueous solution of NaCl) and analyzed via TLC and PXRD at various time intervals to
163 evaluate chemical purity and phase changes.

164

165 2.7 Disc intrinsic dissolution measurements

166 Intrinsic dissolution experiments were performed using a rotating disc apparatus that
167 meets USP specifications (USP, 2012) on a Hanson SR6 dissolution tester (Hanson Research,
168 Chatsworth, CA). Powdered samples (100.0 mg) of AZT-Ac-C and AZT-Ac-A were directly
169 compacted into the stainless steel cylinder of the rotating disc apparatus (resulting in discs at
170 one side of the cylinder with surface area of 0.5 cm²) at 118 MPa (dwell time of 1 min), a
171 compromise compression that produced non-disintegrating discs and did not induce

172 polymorphic transitions and devitrification, as indicated by PXRD analyses. Disc intrinsic
173 dissolution was carried out at 50 rpm in 250 mL of degassed SGF without pepsin at $37 \pm$
174 0.5°C . This medium and its volume was established by considering the chemical stability of
175 AZT-Ac in acidic media (Ribone et al., 2016), its solubility (~ 8 mg/mL, pH 1.2 at 37°C),
176 and the minimum volume required to completely immerse the die. The 250 mL volume
177 maintained sink conditions during the experiment (since the concentrations of AZT-Ac-C and
178 AZT-Ac-A after 25 min were 0.028 and 0.035 mg/mL respectively) and completely immersed
179 the die. Therefore, the concentrations applied in the experiments were below 0.8 mg/mL (10
180 % of the saturation concentration). Aliquots of 5 mL were withdrawn (with replacement) at
181 time intervals of 5, 10, 15, 20 and 25 min, filtered ($0.45\ \mu\text{m}$), and analyzed by UV
182 spectroscopy at 267 nm. In all cases, the first mL was discarded. Dissolution tests were
183 performed in triplicate (AZT-Ac-A) and in duplicate (AZT-AC-C). For the quantification of
184 the concentration of AZT-Ac in the dissolution medium, a standard curve was prepared using
185 five concentration levels. The cumulative amount of dissolved test specimen per initial area
186 was plotted against time. The intrinsic dissolution rate (or mass flux (J) in $\text{mg}/\text{cm}^2/\text{min}$) was
187 calculated from the slope of the regression line (USP, 2012).

188

189 **3. Results and discussion**

190 3.1 Identification of AZT-Ac polymorphs

191 Figure 2 displays the powder patterns for the raw material (Figure 2a), AZT-Ac-C
192 (Figure 2b) and AZT-Ac-A (Figure 2c). As shown in Figures 2a and 2b, the powder patterns
193 of the raw material and AZT-Ac-C were coincident in the position of the diffraction peaks,
194 and no additional reflections were visualized, indicating that they represented the same phase.
195 In contrast, the powder pattern of AZT-Ac-A (Figure 2c) had a broad halo and an absence of
196 diffraction peaks, revealing that it was X-ray amorphous.

197 It is worth of mention that the PXRD patterns of samples obtained by using other
198 crystallization technique such as fast evaporation from different solvents; vapor diffusion
199 crystallization with petroleum ether (35–60 °C) as antisolvent, and polymer induced
200 heteronucleation were coincident (Figures not shown) to those of Figures 2a and 2b,
201 indicating a low likelihood for several crystalline forms of AZT-Ac. Unfortunately, we could
202 not obtain crystals suitable for resolving the crystalline structure of AZT-Ac-C, thus, in order
203 to gain structural information on this form, its SS ¹³CNMR spectrum was obtained (Figure
204 3).

205 As seen in Figure 3a, the spectrum of AZT-Ac-C exhibited well-resolved signals for the
206 11 carbons of the molecule (Figure 1b), with their line widths being all in the range of 30-50
207 Hz, indicating an ordered and crystalline form (Monti et al., 2014). The resonances at 83.3,
208 139.9, 149.9 and 166.9 ppm showed a broadened and split structure but these effects were due
209 to coupling to ¹⁴N quadrupolar nuclei not due to the presence of more than one molecule in
210 the asymmetric unit of AZT-Ac, which thus comprised one molecule of AZT-Ac. In
211 particular, the resonances at 83.5, 139.9 and 166.9 ppm consisted of two lines with relative
212 intensities of 2:1, which is typical of ¹³C nuclei coupled to a single ¹⁴N (Olivieri et al., 1988).
213 Thus, these were assigned to C1', C6 and C4 respectively (Figure 1b, Table S1). In contrast,
214 the resonance at 149.9 ppm consisted of four lines, which is characteristic of a ¹³C nucleus
215 coupled to a pair of ¹⁴N (Olivieri et al., 1988); hence, this resonance was assigned to C2
216 (Table S1). According to the NQS spectrum (Figure 3b), the quaternary carbons of AZT-Ac-
217 C resonated at 110.7 (C5), 149.9 (C2), 157.5 (C1''), 159.1 (C2''), and 166.9 ppm (C4) (Table
218 S1), and it is worth mentioning that the methine carbons (C2' and C5'') were also observed in
219 the NQS spectrum (Figure 3b) because their resonance intensities were severe affected but not
220 totally suppressed during the delay time. C1' (83.5 ppm) and C4' (82.9 ppm) (Table S1) were
221 assigned without ambiguity, as the C1' resonance line shape revealed a residual dipolar

222 interaction structure due to bonding of C1' to N1 while the one of C4' did not. In the case of
223 C3' (59.1 ppm), no residual dipolar coupling was observed, probably due to the mobility of
224 the azide group or the puckering motion of the furanose ring (Kolodziejcki and Klinowski,
225 1999), which can contribute to averaging out the coupling.

226

227 3.2 DSC, TG and HSM

228 The behavior on heating of AZT-Ac-C and AZT-Ac-A was investigated by DSC and
229 TG (Figure 4). The DSC curve of AZT-Ac-C (Figure 4a) exhibited, in the 25-160 °C
230 temperature range, an endotherm at 92.1 °C (extrapolated onset temperature), followed by
231 several small broad endothermic effects. According to the TG data (Figure 4a), the endotherm
232 at 92.1 °C was associated with weight loss, suggesting that the sample melted with
233 decomposition. The interpretation of the DSC events just described was assisted by HSM and
234 TLC. Microscopic observations revealed that the transparent prismatic particles (Figure S1,
235 Supplementary material) of AZT-Ac-C (not embedded in silicon oil in order to provide
236 experimental conditions similar to those in the DSC and TG experiments) melted at about 93
237 °C and upon further heating, the molten phase diminished in size and became brownish, a
238 typical feature of a decomposition process (Sperandeo and de Bertorello, 2001; Sperandeo et
239 al., 2005; Cuffini et al., 2007; Bruno et al., 2010). TLC analysis of the obtained residue
240 confirmed the decomposition of the sample as several spots were detected, with AZT-Ac
241 being absent.

242 The DSC curve of AZT-Ac-A (Figure 4b) showed, in the 25-110 °C temperature
243 range, only a very broad endotherm at 48.5 °C (T_{peak}), resembling a glass transition
244 overlapped with a desolvation process (Kassuha et al., 2015) as the sample was X-ray
245 amorphous and the respective TG curve (Figure 4b) exhibited a gradual weight loss. Taking
246 into account that AZT-Ac-A was obtained by lyophilization from *t*-butanol-water and both

247 solvents can remain in lyophilized solids, as it was observed for other lyophilized samples
248 (Kassuha et al., 2015; Teagarden and Baker, 2002), the occurrence of a desolvation process
249 was considered. Above 110 °C, the DSC curve displayed another very small broad
250 endotherm superimposed with a large exothermic effect that continued at temperatures above
251 170 °C. Both effects had associated a TG weight loss (Figure 4b') that continued above 170
252 °C, typical of a decomposition process that continued at higher temperatures (Sperandeo and
253 de Bertorello, 2001; Cuffini et al., 2007; Bruno et al., 2010). Thus, AZT-Ac-A was
254 visually examined by HSM to assist in the interpretation of the DSC events. Heating the white
255 opaque particles (Figure S1, Supplementary material) of AZT-Ac-A (not immersed in silicon
256 oil) from 25° C revealed that they became almost colorless and compacted at about 60 °C,
257 which was consistent with a glass transition concomitant with a desorption process. The
258 sample started to move (at about 80 °C), became liquefied (at about 103 °C) and on further
259 heating, the molten phase diminished in size and brownish. TLC analysis of the obtained
260 residue confirmed the decomposition of the sample as the AZT-Ac spot was not detected.
261 Further studies using other analytical techniques should be necessary to determine the glass
262 transition temperature of AZT-Ac-A as well as to identify the residual solvents.

263

264 *3.3 Solid-state stability*

265 The solid-state stabilities of AZT-Ac-C and AZT-Ac-A were evaluated at 40 °C/75%
266 RH. Exposure of AZT-Ac-C to the assayed conditions for 14 days did not result in
267 polymorphic conversions as indicated by PXRD. In fact, the powder patterns of AZT-Ac-C
268 (Figure 5a), collected after 7 and 14 days of storage at 40 °C/75% RH did not exhibit new
269 reflections attributable to hydrate formation or polymorphic conversions. However, TLC
270 analysis of an aliquot taken at day 14 revealed the presence of free AZT, indicating that the
271 ester bond of AZT-Ac-C had partially hydrolyzed affording its parent compound; hence its

272 stability was not investigated further. It should be noted that the characteristic peaks of AZT
273 could not be visualized in Figure 5a, suggesting that its quantity was below to the detection
274 limit of PXRD (1-5%) (Pecharsky and Zavalij, 2003). In contrast, exposure of AZT-Ac-A to
275 temperature and moisture provoked its devitrification to AZT-Ac-C as indicated by PXRD.
276 Indeed, the XRD patterns registered at day 7 and 14 (Figure 5b) exhibited various low
277 intensity peaks of AZT-Ac-C superimposed to the amorphous halo, indicating that AZT-Ac-A
278 partly devitrified to its crystalline counterpart. In addition, TLC analyses revealed the
279 presence of free AZT at day 14, indicating that the temperature and humidity promoted its
280 hydrolysis to its parent compound. Therefore, AZT-Ac-C and AZT-Ac-A cannot be stored in
281 the typical conditions of a hot and humid climate without any special storage and handling
282 instructions.

283

284 3.4 Intrinsic dissolution behavior

285 Intrinsic dissolution is a pharmacopeial (USP, 2012; EP, 2013) method for the
286 evaluation of drug powders and it has wide application in characterizing new chemical
287 entities (NCE) during the formulation development since parameters which control the rate of
288 dissolution such as surface area exposed to the medium, temperature, stirring rate, and pH, are
289 kept constant (USP, 2012; Löbmann et al., 2014; Sehic et al., 2010; Kaplan, 1972). In
290 addition, Kaplan (Kaplan, 1972) had suggested that intrinsic dissolution rates (J), determined
291 in the 1-7 pH range at 50 rpm and 37 °C, may be useful to predict absorption problems as
292 compounds with $J > 1$ mg/min/cm² are usually not prone to dissolution rate limited absorption;
293 with $J < 0.1$ mg/min/cm² usually exhibit dissolution rate limited absorption, and with J
294 between 0.1 and 1.0 mg/min/cm² are borderline compounds; thus, additional information
295 would be required to ascertain the effect of dissolution on the absorption rate (Du et al.,
296 2013).

297 The amounts released per initial compact area (mg/cm^2) of AZT-Ac-C and AZT-Ac-A
298 are shown in Figure 6. The profile of AZT-Ac-C (Figure 6a) was a typical linear intrinsic
299 dissolution plot ($R^2 > 0.999$), indicating good linearity between time and amount released per
300 unit area. The intrinsic dissolution rate, calculated from the slope of the regression line, was
301 found to be $0.494 \text{ mg}/\text{min}/\text{cm}^2$. In contrast, the intrinsic dissolution profile of AZT-Ac-A was
302 not linear (Figure 6b), showing an upward curvature that is typical of experimental problems
303 such as physical degradation of the compact by cracking or erosion (USP, 2012). Regression
304 analysis of all the data points of AZT-Ac-A showed that quadratic fitting (*i.e.* second-order
305 polynomial) gave an excellent regression ($R^2 > 0.9995$). Thus, in order to estimate the
306 intrinsic dissolution rate (J) of AZT-Ac-A, linear regression analysis was performed on data
307 points in the initial linear region of the dissolution curve (*i.e.* up to 10 min, inset of Figure 6)
308 as recommended by the United States Pharmacopeia (USP, 2012), which provided an IDR
309 of $0.397 \text{ mg}/\text{min}/\text{cm}^2$. It is worth of mention that after the dissolution experiments, the discs
310 were patted dried and visually examined under a magnifying glass to evaluate if changes had
311 occurred on the surface of discs. No changes in the surface of the compacts of AZT-Ac-C
312 were detected after dissolution. In contrast, the compacts of AZT-Ac-A showed holes and
313 lines, indicating that the surface area of the discs did not remain constant during the assay,
314 and this make an estimate of its IDR speculative at best.

315 According to Kaplan's classification (Kaplan, 1972; Du et al., 2013; Yao et al., 2014),
316 AZT-Ac belonged to the category of borderline NCE as the J values of AZT-Ac-C and AZT-
317 Ac-A were between 0.1 and $1.0 \text{ mg}/\text{min}/\text{cm}^2$. Hence, additional information may be required
318 to ascertain the effect of dissolution on the absorption rate of AZT-Ac.

319 **Conclusions**

320 This investigation contributes to the preformulation assessment of AZT-Ac by
321 exploring some aspects of its solid state properties and inherent stability. Two solid forms of

322 AZT-Ac were prepared and physically characterized by PXRD, SSNMR, DSC, TG and HSM.
323 Although the enzymatic and stability of AZT-Ac in solution it was found good, especially in
324 acidic conditions (Ribone et al., 2016), our research studies demonstrated that under hot and
325 humid climate conditions (40°C/75% RH), the solid state stability of AZT-Ac is not good as
326 its two solid forms partly hydrolyzed to the parent compound AZT after 14 days of storage. In
327 addition, AZT-Ac-A devitrified partially to the crystalline form after 7 days of storage,
328 suggesting that the amorphous form was not optimal to use for further development. The ID
329 rates of AZT-Ac-C and AZT-Ac-A were determined to fall in the range 0.1- 1.0 mg/cm²/min,
330 which suggested that this prodrug could exhibit dissolution rate limited absorption.
331 Therefore, approaches to enhance the solid state stability and dissolution rate of AZT-Ac-C
332 should be considered in a further development.

333

334 **Acknowledgements**

335 This work was supported by SECyT-UNC and FONCyT of Argentina. FPB and DEK
336 are grateful for financial support from the CONICET Type II Doctoral fellowships. DEK also
337 thanks Secretaria de Ciencia, Técnica e Innovación (SeCiTI de San Juan (Argentina) for
338 financial support. We thank Dr. P. Hobson, native speaker, for revision of the manuscript.

339

340 **Declaration of interest: none.**

341

342 **References**

343 Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, et al. 3'-Azido-
344 3'-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7
345 (UGT2B7). Drug Metab Dispos, 2000; 28: 497–502.

346 Bruno FP, Caira MR, Monti GA, Kassuha DE, Sperandeo NR. Spectroscopic,
347 thermal and X-ray structural study of the antiparasitic and antiviral drug nitazoxanide. *J Mol*
348 *Struct*, 2010; 984: 51-57.

349 Cuffini S, Ayala A, Mendes Filho AJ, Ellena J, Mascarenhas Y, et al.
350 Physicochemical Characterization of Deflazacort: Thermal Analysis, Crystallographic and
351 Spectroscopic Study. *Steroids*, 2007; 72: 61-69.

352 Cunha S. Métodos Simples de Formação de Monocristal de Substância Orgânica
353 para Estudo Estrutural por Difração de Raios X. *Quim Nova* 2008; 31: 906-909.

354 D'Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. *Curr*
355 *Clin Pharmacol*, 2008; 3: 20–37.

356 Dalpiaz A, Paganetto G, Pavan B, Fogagnolo M, Medici A, Beggiato S, et al.
357 Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to
358 bypass the active efflux transport systems of the central nervous system. *Mol Pharmaceut*,
359 2012; 9: 957-968.

360 De Clercq E. The design of drugs for HIV and HCV. *Nat Rev Drug Discov*, 2007; 6
361 (12):1001-18.

362 Du W, Zhou Y, Gong Y, Zhao C. Investigation of physicochemical properties and in-
363 vitro in-vivo evaluation of agomelatine polymorphs. *Asian J Pharm Sci*, 2013; 8: 181-190.

364 Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV
365 drugs, saquinavir and zidovudine, from human endothelial cells. *Exp Biol Med*, 2008; 233:
366 1149–1160.

367 European Pharmacopoeia. 8th ed. Strasbourg: Council of Europe, 2013; 2.9.29,
368 Intrinsic dissolution, 331-332.

369 Gandhi RB, Bogardus JB, Bugay DE, Perrone RK, Kaplan MA. Pharmaceutical
370 relationships of three solid state forms of stavudine. *Int J Pharm*, 2000; 201: 221-237.

371 Kaplan SA. Biopharmaceutical considerations in drug formulation design and
372 evaluation. *Drug Metab Rev*, 1972; 1:15-33.

373 Kassuha D, Aiassa V, Bruno F, Cuadra G, Sperandeo N. Preparation and
374 characterization of polymorphs of the glucocorticoid deflazacort. *Pharm Dev Technol*, 2015;
375 20(4): 401-409.

376 Khandazhinskaya AL, Shirokova EA. AZT 5'-Phosphonates: Achievements and
377 Trends in the Treatment and Prevention of HIV Infection. *Acta Naturae*, 2013; 5(3): 54–61.

378 Kolodziejcki W, Klinowski J. ¹³C CP/MAS NMR study of anti-HIV-1 agent AZT.
379 *Chem Phys Letters* 1999; 303: 183-186. [https://doi.org/10.1016/S0009-2614\(99\)00193-1](https://doi.org/10.1016/S0009-2614(99)00193-1)

380 Löbmann K, Flouda K, Qiu D, Tsolakou T, Wang W, Rades T. The Influence of
381 Pressure on the Intrinsic Dissolution Rate of Amorphous Indomethacin. *Pharmaceutics* 2014;
382 6: 481-493.

383 Monti GA, Chattah AK, Garro Linck Y. Solid State Nuclear Magnetic Resonance in
384 Pharmaceutical Compounds. *Annu Rep NMR Spectro*, 2014; 83: 221-269.

385 Moroni GN, Bogdanov PM, Briñón MC. Synthesis and in vitro antibacterial activity
386 of novel 5-*O*-analog derivatives of zidovudine as potential prodrugs. *Nucleos Nucleot Nucl*,
387 2002; 21: 231-241.

388 Narciso P, Bolli A, Fasano M, Ascenzi P. Binding of Anti-HIV Drugs to Human
389 Serum Albumin. *IUBMB Life*, 2014; 56(10): 609–614.

390 Olivieri AC, Frydman L, Grasselli M, Días LE. Analysis of ¹³C, ¹⁴N residual dipolar
391 coupling in the ¹³C CP/MAS NMR spectra of ribonucleosides. *Magn Res Chem*, 1988; 26:
392 281-286.

393 Parang K, Wiebe LI, Knaus EE. Novel approaches for designing 5-*O*-ester prodrugs
394 of 3-azido-2, 3-dideoxythymidine (AZT). *Curr Med Chem*, 2000; 7: 995-1039.

395 Pecharsky VK, Zavalij PY. Fundamentals of Powder Diffraction and Structural
396 Characterization of Materials. Springer Science + Business Media, Inc. 2003, p. 389. ISBN
397 978-0-387-09579-0

398 Price CP, Grzesiak AL, Matzger AJ. Crystalline Polymorph Selection and Discovery
399 with Polymer Heteronuclei. *J Am Chem Soc*, 2005; 127: 5512-5517.

400 Quevedo MA, Briñón MC. In Vitro and in Vivo pharmacokinetic characterization of
401 two novel prodrugs of zidovudine. *Antiviral Res*, 2009; 1: 103-111.

402 Quevedo MA, Ribone SR, Moroni GR, Briñón MC. Binding to human serum
403 albumin of zidovudine (AZT) and novel AZT derivatives. Experimental and theoretical
404 analyses. *Bioorg Med Chem*, 2008; 16: 2779–2790.

405 Raviolo MA, Trincherro-Hernández JS, Turk G, Briñón MC. Synthesis and
406 antiretroviral evaluation of novel derivatives of Zidovudine. *J Braz Chem Soc*, 2009; 20:
407 1870-1877.

408 Ribone, SR, Schenfeld, EM, Madrid M, Pierini AB, Quevedo MA. Evaluation and
409 synthesis of AZT prodrugs with optimized chemical stabilities: experimental and theoretical
410 analyses. *New J Chem*, 2016; 40, 2383-2392.

411 Sehic S, Betz G, Hadzidedi S, Kocova El-Arini S, Leuenberger H. Investigation of
412 intrinsic dissolution behavior of different carbamazepine samples. *Int J Pharm*, 2010; 386:
413 77–90.

414 Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Co-formulated abacavir-
415 lamivudine-zidovudine for initial treatment of HIV infection and AIDS. *Cochrane Database*
416 *Syst Rev*, 2013; 28(3): 1-38.

417 Soares KC, Rediquieri CF, Souza J, Serra CH, Abrahamsson B, Groot DW, et al.
418 Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine
419 (azidothymidine). *J Pharm Sci*, 2013; 102: 2409-2423.

420 Solyev PN, Shipitsin AB, Karpenko IL, Nosik DN. Synthesis and Anti-HIV
421 Properties of New Carbamate Prodrugs of AZT. *Chem Biol Drug Des*, 2012; 80: 947-952.

422 Sperandeo NR, de Bertorello MM. Solid state characterization of potential
423 protozoocidal agents-aminoisoxazolyl naphthoquinones. *Thermochim Acta*, 2001; 378, 67-71.


424 Sperandeo NR, Karlsson A, Cuffini S, Pagola S, Stephens PW. The Crystal Structure
425 and Physicochemical Characteristics of 2-Hydroxy-N- [3(5)-pyrazolyl]-1,4-naphthoquinone-
426 4-imine, a New Antitrypanosomal Compound. *AAPS PharmSciTech*, 2005; 6 (4): E655-
427 E663.

428 Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-
429 solvent systems. *Eur J Pharm Sci*, 2002 15: 115–133.

430 United States Pharmacopeia General Information chapter <1087> Apparent Intrinsic
431 Dissolution-Dissolution Testing Procedures for Rotating Disc and Stationary Disc. In *The*
432 *United States Pharmacopeia and National Formulary USP 35–NF 30*; The United States
433 Pharmacopeial Convention, Inc.: Rockville, MD 2012; 660-663.

434 Yao Y, Lin G, Xie Y, Ma P, Li G, Meng Q, et al. Preformulation studies of
435 myricetin: a natural antioxidant flavonoid. *Pharmazie*, 2014; 69: 19-26.

436




437

438

439 **Figure 1.** Chemical structures of (a) zidovudine (AZT) and (b) AZT-Ac, and atom numbering used in this study.


440



441

442 **Figure 2.** Overlay PXRD data for three representative samples of AZT-Ac. (a) AZT-Ac raw material; (b) AZT-
443 Ac-C (crystallized from acetonitrile), and (c) AZT-Ac-A (obtained by lyophilization from *t*-butanol-water, 20:80
444 v/v).


445



446

447 **Figure 3.** (a) SS ^{13}C NMR and (b) Non-Quaternary Suppression spectra of AZT-Ac-C.

448




449

450

451 **Figure 4.** DSC (non-hermetically sealed pan) and TG (open pan) curves (10 °C/min, flowing N₂ at 50 mL/min)

452 of: (a) AZT-Ac Form I and (b) AZT-Ac-A.


453



454

455 **Figure 5.** PXRD patterns of (a) AZT-Ac-C and (b) AZT-Ac-A after storage at 40°C/75% RH. To allow a
 456 visual comparison, the powder pattern of AZT-Ac-C was included at the top of Figure 5b.

457



458

459 **Figure 6.** Disc Intrinsic dissolution profiles (50 rpm, 250 mL of degassed SGF, 37 ± 0.5 °C) of (a) AZT-Ac-C

460 and (b) AZT-Ac-A. Inset: linear portion of the intrinsic dissolution profile of AZT-Ac-A.

461